Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
- PMID: 39175037
- PMCID: PMC11340159
- DOI: 10.1186/s40001-024-02021-0
Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
Abstract
Enzalutamide (Enz) is commonly utilized as the initial treatment strategy for advanced prostate cancer (PCa). However, a notable subset of patients may experience resistance to Enz, resulting in reduced effectiveness. Utilizing Gene Expression Omnibus (GEO) databases, we identified CBX2 as a crucial factor in mediating resistance to Enz, primarily due to its inhibitory effect on the P53 signaling pathway. Silencing of CBX2 using small interfering RNA (siRNA) led to elevated levels of P53 expression in LNCaP cells. This indicates that CBX2 may have a critical effect on PCa Enz resistance and could serve as a promising therapeutic target for individuals with Enz resistance.
Keywords: CBX2; Enzalutamide; PCa; Prostate cancer; Resistance.
© 2024. The Author(s).
Conflict of interest statement
There are no potential conflicts of interest.
Figures
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
